CARDIFF ONCOLOGY INC (CRDF:NASDAQ)
$1.33 0.01 (0.7576%)
Analysed CARDIFF ONCOLOGY INC (CRDF:NASDAQ) News Sources
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
28-04-2026
yahoo.com
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
14-05-2026
yahoo.com
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist
20-05-2026
yahoo.com
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
21-05-2026
yahoo.com
CRDF: First Quarter 2026 Results
22-05-2026
yahoo.com
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
01-06-2026
yahoo.com
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
02-06-2026
yahoo.com
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
02-06-2026
yahoo.com
CRDF: Phase II Update; Survival Advantage Extended
22-06-2026
yahoo.com
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?
30-06-2026
yahoo.com
What is the current price of CARDIFF ONCOLOGY INC (CRDF:NASDAQ)?
The current price of CARDIFF ONCOLOGY INC (CRDF:NASDAQ) is $1.33.
CARDIFF ONCOLOGY INC (CRDF:NASDAQ) absolute price change since previous trading day?
The absolute price change of CARDIFF ONCOLOGY INC (CRDF:NASDAQ) since the previous trading day is $0.01.
CARDIFF ONCOLOGY INC (CRDF:NASDAQ) percentage price change since previous trading day?
The percentage price change of CARDIFF ONCOLOGY INC (CRDF:NASDAQ) since the previous trading day is 0.7576%.
What is the most recent average sentiment score for CARDIFF ONCOLOGY INC (CRDF:NASDAQ)?
The most recent average sentiment score for CARDIFF ONCOLOGY INC (CRDF:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for CARDIFF ONCOLOGY INC (CRDF:NASDAQ)?
The most recent sentiment for CARDIFF ONCOLOGY INC (CRDF:NASDAQ) is .
SEC-8K** Filing Available For CARDIFF ONCOLOGY INC (CRDF:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.